October 6, 2026
News
September 3, 2026
Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers
September 3, 2026
Researchers say their ability to create Elenagen was only possible because of their opposition to dominant biotech doctrine
September 3, 2026
Study demonstrates significant overall survival benefit with elenagen plus gemcitabine in one of the deadliest gynecologic malignancies Reports and Proceedings CureLab Oncology Inc.
September 3, 2026
Peer-reviewed in the International Journal of Gynecological Cancer Elenagen plus chemotherapy lived significantly longer than those who received chemotherapy alone Median overall survival increased from approximately 13 months to over 25 months.
August 31, 2026
Renowned NYU Langone physician-scientist brings deep expertise in adenosine biology, inflammation, tissue repair, and translational research
August 20, 2026
Experienced physician-executive brings more than two decades of oncology, hematology, immunotherapy, and cell-therapy development expertise
June 23, 2026
June 23, 2026
Alex Shneider, Founder and CEO of CureLab Oncology, discusses DNA-based immunotherapies, inflammation-driven cancer biology, intelligent combination therapies, and the emerging science of reprogramming the tumour microenvironment.
June 16, 2026
Dr. Alex Shneider, CEO of Curelab Oncology and the developer of Elenagen joins eHealth Radio and the Health News and Cancer Information Channels to discuss this breakthrough.
September 16, 2021
The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy
August 11, 2021
Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers; at the center of the study is CureLab Oncology’s Elenagen, an experimental DNA therapy
March 15, 2021
Patent registration in Hong Kong paves the way to establishing business operations in PRC
January 22, 2021
Based on a scientifically solid proof of concept in dogs and cats, a licensed international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding and to become profitable within 36 months of raising funds.